Recruiting
Phase 2

Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma

Sponsor:

M.D. Anderson Cancer Center

Code:

NCT04189757

Conditions

Mantle Cell Lymphoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Acalabrutinib

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information